DK2044026T3 - Fremgangsmde til behandling af cerebral glioma tumor - Google Patents

Fremgangsmde til behandling af cerebral glioma tumor

Info

Publication number
DK2044026T3
DK2044026T3 DK07719115.3T DK07719115T DK2044026T3 DK 2044026 T3 DK2044026 T3 DK 2044026T3 DK 07719115 T DK07719115 T DK 07719115T DK 2044026 T3 DK2044026 T3 DK 2044026T3
Authority
DK
Denmark
Prior art keywords
procedures
treatment
glioma tumor
cerebral glioma
cerebral
Prior art date
Application number
DK07719115.3T
Other languages
English (en)
Inventor
Jack Gordon Parsons
Vijaya Kenche
Penelope Jane Huggins
Gaik Beng Kok
Ashley Bush
Original Assignee
Prana Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prana Biotechnology Ltd filed Critical Prana Biotechnology Ltd
Application granted granted Critical
Publication of DK2044026T3 publication Critical patent/DK2044026T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK07719115.3T 2006-06-22 2007-06-22 Fremgangsmde til behandling af cerebral glioma tumor DK2044026T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81577906P 2006-06-22 2006-06-22
PCT/AU2007/000876 WO2007147217A1 (en) 2006-06-22 2007-06-22 Method of treatment of glioma brain tumour

Publications (1)

Publication Number Publication Date
DK2044026T3 true DK2044026T3 (da) 2014-06-30

Family

ID=38833006

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07719115.3T DK2044026T3 (da) 2006-06-22 2007-06-22 Fremgangsmde til behandling af cerebral glioma tumor

Country Status (9)

Country Link
US (1) US8163760B2 (da)
EP (1) EP2044026B1 (da)
JP (1) JP5415942B2 (da)
CN (1) CN101589026B (da)
AU (1) AU2007262670B2 (da)
CA (1) CA2656825C (da)
DK (1) DK2044026T3 (da)
ES (1) ES2474865T3 (da)
WO (1) WO2007147217A1 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
WO2007118276A1 (en) * 2006-04-14 2007-10-25 Prana Biotechnology Ltd Method of treatment of age-related macular degeneration(amd)
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US9321730B2 (en) 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
KR20100116206A (ko) 2008-02-01 2010-10-29 다케다 야쿠힌 고교 가부시키가이샤 Ｈｓｐ90 저해제로서의 옥심 유도체
GB0806794D0 (en) * 2008-04-15 2008-05-14 Ludwig Inst Cancer Res Therapeutic compounds
CA2737219C (en) * 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
DK2379510T3 (da) * 2008-12-24 2016-12-19 Prana Biotechnology Ltd Quinazolinonforbindelser
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
CN102603628B (zh) * 2010-12-22 2016-08-17 香港理工大学 作为抗癌试剂的喹啉衍生物
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
FR2984317B1 (fr) * 2011-12-20 2015-02-27 Univ Rennes Composes chelateurs de metal presentant au moins une chaine polyaminee.
EP2802572B1 (en) 2012-01-13 2018-11-07 President and Fellows of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JP6027267B2 (ja) * 2012-12-27 2016-11-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｏｍｔ阻害剤
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
SG11201508328PA (en) 2013-04-19 2015-11-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN105829285A (zh) 2013-10-23 2016-08-03 中外制药株式会社 喹唑啉酮和异喹啉酮衍生物
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN107001360B (zh) 2014-12-02 2020-09-18 普拉纳生物技术有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN107438607B (zh) 2015-02-20 2021-02-05 因赛特公司 作为fgfr抑制剂的双环杂环
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019067503A1 (en) * 2017-09-26 2019-04-04 Dana-Farber Cancer Institute, Inc. NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
AU2019262195B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
US11708353B2 (en) 2018-06-08 2023-07-25 The General Hospital Corporation Inhibitors of prolyl-tRNA-synthetase
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
CN111471012B (zh) * 2019-01-23 2023-04-25 鲁南制药集团股份有限公司 一种蜈蚣喹啉类化合物、制备方法及其应用
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN110240590A (zh) * 2019-07-16 2019-09-17 广州新民培林医药科技有限公司 一类嘧啶喹啉衍生物及其制备方法和应用
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20230116403A1 (en) 2019-12-02 2023-04-13 Storm Therapeutics Limited Polyheterocyclic compounds as mettl3 inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
TW202216713A (zh) 2020-07-02 2022-05-01 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CN113214249B (zh) * 2021-04-23 2023-09-19 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
TW202337453A (zh) 2022-03-17 2023-10-01 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物
CN116410132B (zh) * 2023-02-23 2024-07-09 广东工业大学 一种8-羟基喹啉类化合物及其制备方法和在制备抗肿瘤药物上的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265923T3 (es) 1999-03-24 2007-03-01 Anormed Inc. Compuestos heterociclicos que se unen a receptores de quimiocinas.
NZ520300A (en) * 2000-01-24 2004-05-28 Kinacia Pty Ltd Morpholino-substituted pyridopyrimidine, quinolone and benzopyranone derivatives that inhibit the enzyme phosphoinositide (PI) 3-kinase
AU2002230056A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Indole derivatives and their uses as heparanase inhibitors
KR20040004705A (ko) * 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
EP1478646A1 (en) 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
AU2003282726B2 (en) 2002-10-03 2010-10-07 Targegen, Inc. Vasculostatic agents and methods of use thereof
WO2004031161A1 (en) * 2002-10-04 2004-04-15 Prana Biotechnology Limited Neurologically-active compounds
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
WO2006031806A2 (en) 2004-09-10 2006-03-23 Atherogenics, Inc. 2-thiopyrimidinones as therapeutic agents
JP5144532B2 (ja) * 2005-11-30 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔ阻害剤及び用法
DE102005059479A1 (de) 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
WO2007118276A1 (en) * 2006-04-14 2007-10-25 Prana Biotechnology Ltd Method of treatment of age-related macular degeneration(amd)

Also Published As

Publication number Publication date
EP2044026A4 (en) 2009-08-05
WO2007147217A1 (en) 2007-12-27
JP5415942B2 (ja) 2014-02-12
CN101589026A (zh) 2009-11-25
US20100069393A1 (en) 2010-03-18
EP2044026A1 (en) 2009-04-08
JP2009541223A (ja) 2009-11-26
AU2007262670A1 (en) 2007-12-27
CN101589026B (zh) 2013-10-16
EP2044026B1 (en) 2014-03-26
AU2007262670A2 (en) 2009-03-26
US8163760B2 (en) 2012-04-24
CA2656825C (en) 2013-12-10
ES2474865T3 (es) 2014-07-09
CA2656825A1 (en) 2007-12-27
AU2007262670B2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
DK2044026T3 (da) Fremgangsmde til behandling af cerebral glioma tumor
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
HK1208237A1 (en) Methods for the treatment of gout
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
CR10679A (es) Novel anti-cd38 antibodies for the treatment of cancer
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2019683T4 (da) Indgivelse af vækstfaktorer til behandling af CNS-lidelser
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2545939T3 (da) Tetrahydrobiopterin til behandling af tilstande associeret med forhøjede phenylalaninniveauer
BRPI0821779A2 (pt) tratamento terapêutico de câncer
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK2440230T3 (da) Behandlingsregimener til behandling af neurologisk sygdom
DK2162149T3 (da) Vaccine til forebyggelse af brystkræfttilbagefald
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus